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elderly (225±41 ms) than in younger patients (208±31 msec) (p<0.001). Increased atrial
refractory period and age > 70 years were independent factors of decreased AF inducibil-
ity. Conclusion : AF inducibility is paradoxically decreased in elderly patients. The AF
induction is facilitated by the presence of a short atrial refractory period in patients
younger than 70 years and programmed atrial stimulation should be interpreted cau-
tiously in these patients. In the opposite, the increase of atrial refractory period could pro-
tect the patients older than 70 years against AF induction.
ORAL CONTRIBUTIONS
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10:30 a.m.
839-1 The Long-Term Effect of Surgical Myectomy on Survival 
in Patients With Obstructive Hypertrophic 
Cardiomyopathy
Steve R. Ommen, Iacopo Olivotto, Martin S. Maron, Sandro Betocchi, Franco Cecchi, 
Michael J. Ackerman, Bernard J. Gersh, Joseph A. Dearani, Hartzell V. Schaff, Rick A. 
Nishimura, Barry J. Maron, Mayo Clinic, Rochester, MN
Background: Surgical septal myectomy is the definitive treatment for relief of drug-refrac-
tory symptoms in hypertrophic cardiomyopathy (HCM). Recent data document reduced
survival when left ventricular outflow (LVOT) obstruction is present. However, the poten-
tial effects of myectomy on long-term survival are unresolved.
Methods: Overall mortality was assessed in 1337 HCM pts evaluated between 1983-
2001: (1) 289 consecutive pts underwent isolated surgical myectomy at Mayo Clinic for
advanced symptoms attributable to LVOT obstruction; (2) 228 other pts with LVOT
obstruction were managed without surgery; (3) 820 pts had nonobstructive HCM. Sur-
vival after myectomy was compared to age and sex matched general population, nonop-
erated obstructive pts, and nonobstructive pts.
Results: Patients were 45 ± 20 years old, 58% were males, LV wall thickness was 22 ± 6
mm, the average resting gradient was 68 ± 37mmHg among the pts with LVOT obstruc-
tion. Including 4 operative deaths (procedural mortality, 1.4%), survival after myectomy at
1, 5, and 10 years was 98%, 96%, and 83%, respectively. This survival did not differ sta-
tistically from the age and sex matched general population, nor the pts with nonobstruc-
tive HCM (98%, 95%, 88%). Myectomy pts had more favorable survival than nonoperated
obstructive pts (90%, 80%, and 67%, log-rank p <0.0001). Multivariate Cox modelling
with all relevant co-variates showed that myectomy (hazard ratio 0.20, p<0.0001) was
independently associated with more favorable long-term survival.
Conclusion: Surgical septal myectomy performed for the relief of LVOT obstruction and
severe drug-refractory symptoms is associated with long-term survival equivalent to that
of an age and sex matched general population. Although these data are retrospective
and nonrandomized, they strongly suggest that myectomy reduces the excess mortality
risk associated with the presence of LVOT obstruction.
10:45 a.m.
839-2 Mechanism of Systolic Anterior Motion and 
Regurgitation Post Septal Ablation in Hypertrophic 
Cardiomyopathy
Francesca Nesta, Danita M. Yoerger, Michael H. Picard, Michael A. Fifer, Igor F. Palacios, 
Gus J. Vlahakes, Robert A. Levine, Judy Hung, Massachusetts General Hospital, 
Boston, MA
Background: Systolic anterior motion of the mitral valve (SAM) in hypertrophic cardi-
omyopathy (HCM) is secondary to both outflow tract narrowing and primary structural
abnormalities of the mitral apparatus: the papillary muscles (PM) and leaflets are shifted
anteriorly into the LV outflow path, causing SAM with regurgitation (MR). Clinical obser-
vations suggest that relief of obstruction by septal ablation (SAb) does not always cause
resolution of SAM and MR. We tested the hypothesis that persistent SAM relates to mal-
position of the mitral apparatus, and that this finding can predict persistence of SAM.
Methods: We reviewed echoes of 30 patients with HCM before and 3 months post SAb.
We assessed anterior leaflet malposition by the antero-posterior projection of the coapta-
tion point onto the mitral annular diameter (A/D ratio) in early systole. MR was assessed
by proximal jet in the LAX view. Results: Most patients (22/30=73%) had SAM at 3
months despite successful SAb (gradient reduction > 50%), and had more anterior mal-
position and less MR reduction than those without SAM: A/D 0.44 vs 0.57, MR proximal
jet reduction by 7% vs 51%, p < 0.0001. Anterior malposition was also present prior to
SAb, with A/D < 0.4 being predictive of SAM post SAb (p<0.007). Conclusions: SAM
and its related MR are not always eliminated by SAb. MV malposition is a strong determi-
nant and predictor of SAM and MR reduction post SAb and may represent a new thera-
peutic target during ablation procedures. 
11:00 a.m.
839-3 Frequency, Spectrum, and Phenotype of Hypertrophic 
Cardiomyopathy Patients With Multiple Sarcomeric 
Mutations
Sara L. Van Driest, Steve R. Ommen, Melissa L. Will, Vlad C. Vasile, Susan Chung, A. 
Jamil Tajik, Bernard J. Gersh, Michael J. Ackerman, Mayo Clinic, Rochester, MN
Background: Hypertrophic cardiomyopathy (HCM) is caused by pathogenic mutations
involving 8 genes that encode critical proteins comprising the sarcomere. Here, we deter-
mine the frequency, spectrum, and phenotype associated with complex genetic status
(i.e. > 1 sarcomeric mutation) in a cohort of unrelated patients (pts) evaluated at a tertiary
outpatient HCM clinic.
Methods: DNA was obtained from 389 unrelated HCM pts and analyzed for mutations in
myosin binding protein C encoded by MYBPC3, β -myosin heavy chain (MYH7), regula-
tory and essential light chains (MYL2 and MYL3), troponin T (TNNT2), troponin I
(TNNI3), α -tropomyosin (TPM1), and actin (ACTC) using polymerase chain reaction,
denaturing high performance liquid chromatography, and DNA sequencing. Clinical data
were extracted from pt records blinded to pt genotype.
Results: Of the 389 HCM pts, 151 (38.8%) harbored at least one putative pathogenic
mutation. Eleven pts (2.8% of total and 7.2% of genotyped subset) had 2 putative sarco-
meric mutations: compound MYBPC3 in 2 pts, MYBPC3 and MYH7 (3), MYBPC3 and
TNNT2 (2), MYBPC3 and TNNI3 (1), MYBPC3 and TPM1 (1), compound MYH7 (1), and
MYH7 and TNNT2 (1). When compared to pts with single sarcomeric mutations, or no
sarcomeric mutations, pts with multiple mutations were younger at diagnosis (21.7 ± 11
years vs 36.4 ± 17 vs 45.1 ± 19, p <0.005, had greater hypertrophy (maximum left ven-
tricular wall thickness = 24.6 ± 12 mm vs 22.8 ± 6 vs 20.7 ± 6, p <0.05), and more fre-
quently received an ICD (36% vs 24% vs 10%, p = 0.0002). However, those with multiple
mutations were not more likely to have had a surgical myectomy than those with a single
mutation or no identifiable sarcomeric mutation.
Conclusion: This study represents a comprehensive mutational analysis searching for
multiple genetic defects in a large HCM cohort from a single tertiary referral center. Com-
plex genetic status was found in nearly 3% of HCM pts. On average, pts with multiple sar-
comeric mutations were diagnosed 20 years earlier and displayed the greatest degree of
hypertrophy. The possibility of multiple mutations involving the sarcomere adds further
complexity to the development and implementation of clinical molecular genetic testing
for HCM.
11:15 a.m.
839-4 Treatment With Antioxidant N-Acetylcysteine Reverses 
Interstitial Fibrosis in a Mouse Model of Human 
Hypertrophic Cardiomyopathy Mutation
Natalia Tsybouleva, Tripti Halder, Rajnikant Patel, Silvia Lutucuta, Gilberto De Freitas, 
Masakuni Ishiyama, Blase Carabello, Ali J. Marian, Baylor College of Medicine, Houston, 
TX
The genetic basis of human hypertrophic cardiomyopathy (HCM) is known but the patho-
genesis of its phenotypes is unknown. We have generated transgenic mice by cardiac-
restricted expressing mutant cardiac troponin T (cTnT)-Q92 protein, known to cause
HCM in humans; which exhibits enhanced systolic function, interstitial fibrosis (IF) and
myocyte disarray. Since oxidative stress is implicated in the pathogenesis of fibrosis, we
tested whether treatment with anti-oxidant N-acetyl cysteine (NAC) could reverse or
attenuate IF in the cTnT-Q92 mice. We performed a placebo-controlled study and ran-
domized 24 mice to placebo or NAC (1g/Kg/d) and include 12 non-transgenic (NTG) mice
as controls. We performed echocardiography prior to and after 16 weeks of therapy fol-
lowed by histological and molecular characterization. Transgenic mice had higher left
ventricular (LV) ejection fraction and smaller LV end systolic diameter and smaller heart
weight/body weight (HW/BW) as compared to NTG mice at the baseline. No significant
differences in the body weight, male/female ratio, mean age, and heart rates were
present among the three groups. Treatment with NAC reduced concentrations of alondi-
aldehyde and 4-hydroxy-2(E)-nonenal, indices of oxidative stress, in the left ventricular
tissue (NTG: 3.0 ± 0.6; Placebo: 3.5 ± 0.4; NAC: 2.3 ± 0.3, p=0.01). Similarly, collagen
volume fraction (CVF) was normalized (NTG: 3.4% ± 0.9; Placebo: 7.8 ± 1.7; NAC: 3.8 ±
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1.4, respectively, p=0.003). HW/BW, LV wall thickness and myocyte disarray were
unchanged with therapy. Levels of oxidized nuclear but not mitochondrial DNA was
increased in the cTnT-Q92 mice and reduced to normal in the NAC group. Similarly,
expression levels of signaling kinases p-ERK1/2 were increased in the cTnT-Q92 and
normalized with NAC. Thus, treatment with anti-oxidant NAC reduces myocardial oxida-
tive stress and normalizes IF in a mouse model of hypertrophic cardiomyopathy. The
results in a genetic animal model of HCM, show the potential salutary effects of NAC in
reversal of interstitial fibrosis, implicated in arrhythmogenesis, in HCM, which is the most
common cause of sudden cardiac death in the young and a major cause of mortality and
morbidity in elderly.
11:30 a.m.
839-5 Two Transgenic Animal Models Expressing Human 
Troponin T Gene Mutations: One Exhibiting Dilated 
Cardiomyopathy (W141) and the Other Exhibiting 
Hypertrophic Cardiomyopathy (Q92)
Jasvinder Sidhu, Duanxiang Li, Zhinong Wang, A.J. Marian, Francesco J. DeMayo, 
George E. Taffet, Robert Roberts, Baylor College of Medicine, Houston, TX
Background: The usual response of the heart is hypertrophy. Decompensation and sub-
sequent heart failure often occurs after transition from hypertrophy to dilatation but
appears to reflect an inhibition of growth. Troponin T (cTnT) mutations have been identi-
fied to cause familial hypertrophic cardiomyopathy (HCM) and others familial dilated car-
diomyopathy (DCM). Thus, different mutations of the same gene induce different growth
patterns. HCM is induced by cTnT Q92 and DCM by cTnT W141 mutations.
Methods: We generated a transgenic mouse (TM) expressing the cTnT Q92 mutation
with a phenotype of HCM and a TM expressing the cTnT W141 with a phenotype of DCM
using alpha MHC as the cardiac specific promotor.
Results: The HCM phenotype (cTnT Q92) has normal heart size with sarcomere disarray,
fibrosis and an increased cardiac ejection rate 73.9 ± 9.4. In contrast, the DCM pheno-
type cTnT W141 has a large dilated heart without fibrosis but with decreased contractility.
Echo analysis was normal at 4 weeks but at 12 weeks showed: Diastolic left ventricular
dimension (LVD) in non-transgene (NT) was 3.68 + .06 versus 4.77 + .20 (p< .05) in TM;
systolic LVD of 2.32 + .09 in NT versus 4.01 + .20 in TM; fractional shortening rate of NT
was 0.37 + .01 versus 0.16 + .009 in TM; and peak ejection rate of 113 + 5 in NT versus
84 + 4 in TM. Gene microarray and northern analysis of myocardial gene expression in
HCM and DCM were performed for markers associated with a hypertrophic growth
response: Expression of IGF and ANP was normal in HCM and DCM. In contrast, skele-
tal alpha actin was decreased in HCM but increased in DCM. BNP normal in HCM was
increased in DCM. GP130, increased in HCM was decreased 1 to 2 fold in DCM. Conclu-
sion: GP130 a cytokine receptor claimed to be necessary for the hypertrophic growth
response was down regulated in our DCM model and thus, may play a pivotal role in the
lack of a hypertrophic growth response. Differential analysis of the GP130 pathway in the
two models should determine whether this pathway is responsible for lack of the growth
response in DCM.
11:45 a.m.
839-6 Role of Left Atrial Contractile Function in Functional 
Capacity of Patients With Hypertrophic Nonobstructive 
Cardiomyopathy
Yukitaka Shizukuda, Vandana Sachdev, Cynthia L. Brenneman, Charles W. Birdsall, 
Lameh Fananapazir, Jonathan F. Plehn, National Heart, Lung, and Blood Institute, 
Bethesda, MD
Background: Left atrial (LA) dilatation and reduced atrial contractile function have been
demonstrated in symptomatic patients with hypertrophic, non-obstructive cardiomyopa-
thy (HNCM), suggesting the presence of a primary atrial myopathy. Since LA contractile
function partially governs left ventricular (LV) preload reserve and maintenance of the
Frank-Starling mechanism, LA systolic dysfunction could provide a mechanism for exer-
cise intolerance in HNCM. We, therefore, evaluated LA contractile function in 50 patients
with HNCM (mean age=37+10 years, 29 men/21 women) with normal LVEF
(mean=69±6%) who were stratified for symptoms of congestive heart failure. Methods:
We analyzed LA volume normalized to body surface area, active atrial ejection fraction
(LAEF), ejection force (LAF), and kinetic energy (LAKE), in asymptomatic (Group 1,
n=19) and symptomatic (Group 2, n=31) subjects and compared these parameters to
symptom-limited metabolic stress testing performed within one week of echocardio-
graphic examination. Results: MRI-derived LV mass was similar between Groups 1 and 2
(mean=229 +68 vs. 223 + 78 gms, respectively, p=NS) and there were no differences in
LAEF, LAF or LAKE in symptomatic versus asymptomatic subjects [59.8 +19.9% vs.
60.6+22.8%, 14.7+8.7 vs. 15.6+11.2 (kdyne), 16.6+19.7 vs. 10.4+13.0 (kerg), respec-
tively]. While resting LAEF correlated weakly with exercise time (r=0.319, p<0.05), it did
not predict MVO2 or anaerobic threshold (p=NS for both). Neither were LAF nor LAKE
associated with any objective exercise parameter. Maximum LA volume, an index of LA
volumetric remodeling, was inversely correlated with peak MVO2 (r=-0.32, p<0.05). Con-
clusion: These data suggest that resting atrial contractile function is not a determinant of
functional capcity in patients with HNCM. Possibly, atrial contractile reserve associated
with exercise might be a more important factor for limitation of functional capacity in these
patients.
ORAL CONTRIBUTIONS
842 Heart Failure and Anemia
Tuesday, March 09, 2004, 10:30 a.m.-Noon
Morial Convention Center, Room 257
10:30 a.m.
842-1 Anemia in Diastolic Heart Failure Is Frequent and 
Associated With Worse Outcome
Steffen Brucks, William C. Little, Tania Chao, Ronald L. Rideman, Bharathi Upadhya, 
Deborah Wesley-Farrington, David C. Sane, Wake Forest University School of Medicine, 
Winston-Salem, NC
Background: Many patients with heart failure (HF) and a reduced ejection fraction (EF)
have anemia. The prevalence and importance of anemia in patients with HF and a nor-
mal EF (diastolic HF) are not known. Thus, we hypothesize that anemia is common in
diastolic HF and associated with a worse outcome.
Methods: We evaluated 137 patients with clinical evidence of HF and a normal EF (>
0.50).
Results: The age was 65±15 (mean ± SD) years, and 58% were women. Anemia (hemo-
globin, Hb, < 12 gm/dl in women; < 13 gm/dl in men) was common, occurring in 45% of
patients. Patients with and without anemia had similar ages (65±15 vs 65±14), EF
(0.62±0.08 vs 0.61±0.07), LV mass (213±77 vs 193±85 gms), and systolic mitral annular
velocity (6.8±1.5 vs 6.9±2.1 cm/sec). Patients with anemia had a higher brain natriuretic
peptide (BNP) (322±330 vs 160±240 pg/ml, p<0.001), worse diastolic dysfunction grade
by mitral Doppler (1.3±8 vs 0.8±7, p<0.001), and a higher ratio of peak mitral inflow
velocity to mitral annular velocity (E/EM) (13.5±6.5 vs 9.7±4.2, p<0.001) compared to
patients without anemia. Reduced Hb concentration correlated with both elevated BNP
(r2=0.15, p<0.0001) and E/EM (r2=0.15, p<0.0001). Patients with anemia had a reduced
two-year cardiac hospitalization-free survival (hazard ratio 2.0, p<0.05)
Conclusion: Anemia is common in pts with HF and a normal EF (diastolic HF) and is
associated with greater elevations in BNP, more severe diastolic dysfunction, and a
worse prognosis.
10:45 a.m.
842-2 Hemoglobin Level Is Associated With Mortality and 
Hospitalization in Patients With Severe Chronic Heart 
Failure: Results From the COPERNICUS Study
Stefan D. Anker, Andrew JS Coats, Ellen B. Roecker, Paul Mohacsi, Jean Rouleau, 
Henry Krum, Armin Scherhag, Milton Packer, for the COPERNICUS study group, 
National Heart and Lung Institute, London, United Kingdom, Applied Cachexia Research, 
Charite, Berlin, Germany
Background: Anemia has been shown to be a risk factor for mortality in mild to moder-
ate chronic heart failure (CHF), but its importance in severe CHF and its ability to predict
hospitalization has not been defined.
Methods: We evaluated the relationship between hemoglobin level and mortality and
hospitalization in 2286 patients (1822 men, 464 women) with severe CHF enrolled in the
COPERNICUS study. All enrolled patients had dyspnea or fatigue at rest or on minimal
exertion for at least 2 months and a left ventricular ejection fraction <25%.
Results: There was a highly significant (P<0.0001) but small (r = -0.089) inverse relation-
ship between baseline hemoglobin and creatinine levels. Patients with low hemoglobin
were at significantly higher risk of a major clinical events, the magnitude of risk decreas-
ing with increasing hemoglobin, both in univariate analyses (all P<0.001) and in multivari-
ate analyses which adjusted for sex and other predictors of risk, including age, left
ventricular ejection fraction, creatinine, body mass index, systolic blood pressure, CHF
etiology and treatment with carvedilol (all P<0.01). Mean creatinine levels and one-year
Kaplan-Meier event rates are shown below: 
Conclusion: Low hemoglobin is an independent risk factor for adverse outcomes in
patients with severe HF. Whether correction of anemia improves outcomes in CHF war-
rants further study.
Table
Hemoglob
in(g/dL)
N Creatinine 
(µmol/L)
All-Cause 
Mortality (%)
Death or HF 
Hospitalization 
(%)
Death or Any 
Hospitalization 
(%)
<11.0 115 151.5 23.2 46.6 64.1
11.0 - 
<12.5
315 135.8 16.7 36.1 51.0
12.5 - 
<13.5
432 133.2 13.5 30.5 48.3
13.5 - 
<15.0
834 132.7 15.6 31.9 45.5
15.0 - 16.5 463 131.2 13.1 26.5 42.9
>16.5 127 131.5 9.0 25.5 38.0
